Related
Computational Approach Identifies Genetic Causes of Three Previously Unexplained Rare Diseases
Rare Daily Staff Researchers at the Icahn School of Medicine at Mount Sinai and colleagues have discovered […]
Read moreA Venture Philanthropist Makes the Case for Advocates Taking Equity
Debra Miller’s son Hawken was diagnosed with Duchenne muscular dystrophy at the age of 5. Rather than […]
Read moreCF Foundation Invests Up to $2 Million in Nanite to Explore a Novel Delivery Method of Genetic Therapies to the Lung
Rare Daily Staff The Cystic Fibrosis Foundation is investing up to $2 million in Nanite to develop […]
Read moreSeamless Launches with $12.5 Million to Advance Gene Editing Platform Based on Programmable Recombinases
Rare Daily Staff Seamless Therapeutics raised $12.5 million (€11.8 million) in a seed financing round to accelerate […]
Read moreAldena Raises $30 Million to Develop siRNA Therapies for Immuno-Dermatology Indications
Rare Daily Staff Aldena Therapeutics, which is developing siRNA-based therapies for dermatological indications, unveiled itself saying it […]
Read moreMediar Raises $105 Million to Advance Portfolio of First-in-Class Therapies Targeting Fibrosis
Rare Daily Staff Mediar Therapeutics, a biotechnology company advancing a portfolio of first-in-class therapies that halt and […]
Read moreRare Daily Staff Eton Pharmaceuticals, a company focused on developing and commercializing treatments for rare diseases, said […]
Read moreFDA Lifts Part of Partial Hold on Stoke’s Dravet Drug Trial to Allow Administration of Higher Single Dose
FDA Lifts Part of Partial Hold on Stoke’s Dravet Drug Trial to Allow Administration of Higher Single […]
Read moreProtagonist Therapeutics Reports Positive Results in PV
Rare Daily Staff Protagonist Therapeutics reported positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of […]
Read more